| Market Capitalization (Millions $) |
1,587 |
| Shares
Outstanding (Millions) |
124 |
| Employees |
92 |
| Revenues (TTM) (Millions $) |
139 |
| Net Income (TTM) (Millions $) |
-37 |
| Cash Flow (TTM) (Millions $) |
27 |
| Capital Exp. (TTM) (Millions $) |
0 |
Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics Inc is a pharmaceutical company focused on developing and commercializing innovative immunology and dermatology therapies to treat immune-mediated dermatological diseases, including psoriasis, atopic dermatitis, and seborrheic dermatitis. The company was founded in 2016 and is headquartered in Westlake Village, California.
Arcutis Biotherapeutics' pipeline includes several dermatology drug candidates, including ARQ-252, a topical treatment for chronic hand eczema that is currently in Phase 3 clinical trials; ARQ-154, a topical cream for the treatment of seborrheic dermatitis that has completed Phase 2 clinical trials and is expected to enter Phase 3 trials; and ARQ-171, a topical foam formulation currently in Phase 2 clinical trials for the treatment of atopic dermatitis.
The company's lead product candidate is ARQ-151, a topical cream for the treatment of plaque psoriasis. ARQ-151 received FDA approval in December 2020 and became available on the market in February 202
Beyond its dermatology pipeline, Arcutis Biotherapeutics is developing ARQ-531, a small-molecule inhibitor for the treatment of B-cell malignancies and other blood cancers. ARQ-531 is currently in Phase 1 clinical trials.
Arcutis Biotherapeutics has partnered with several leading pharmaceutical companies, including LEO Pharma and SQ Innovation, to advance its pipeline and bolster its research and development efforts. The company's goal is to provide innovative and effective treatments for patients suffering from dermatological diseases, and to become a leading player in the dermatology and immunology markets.
Company Address: 3027 Townsgate Road Westlake Village 91361 CA
Company Phone Number: 418-5006 Stock Exchange / Ticker: NASDAQ ARQT
|
49.25 %